Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Ayisha Sharma

News Reporter

Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two decades after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Corrected: Trump's broad tariffs could mark a 'double whammy' for pharma after FDA cuts

Day after mass FDA firings, new commissioner addresses remaining staff, focusing on 'MAHA' vision

FDA cuts stir buyer’s remorse for some biopharma leaders, once excited by Trump

Q&A: John Crowley warns biotech is 'dangerously close' to breaking, as tariff threat, markets batter industry

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

No­var­tis li­cens­es Ky­orin’s pre­clin­i­cal chron­ic hives can­di­date for $55M up­front

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront